JAK2

Cellenkos® enters into Sponsored Research Agreement with Icahn School of Medicine at Mount Sinai, New York.

Retrieved on: 
Monday, April 1, 2024
Research, Pacritinib, JAK2, Bone marrow, Blood transfusion, CXCR4, Inflammation, Patient, University, Ruxolitinib, Clinical trial, CXCL12, Fedratinib, Safety, Pancreatic serous cystadenoma, University of California, Davis, MD Anderson Cancer Center, Albert Einstein Israelite Hospital, Pharmaceutical industry

Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.

Key Points: 
  • Research exploring CK0804 (CXCR4-enriched, allogeneic, cord blood-derived T-regulatory cells) for treatment of myelofibrosis patients.
  • This research will be conducted under the guidance of Ronald Hoffman, MD, Albert A. and Vera G. List Professor of Medicine and Director of the Myeloproliferative Disorders Research Program at The Tisch Cancer Institute- Mount Sinai.
  • CK0804 is a novel allogeneic, CXCR4 enriched, Treg cell therapy product that utilizes Cellenkos' proprietary CRANE® technology to generate disease specific products.
  • Dr. Ronald Hoffman serves as a paid consultant for Cellenkos.

Global Psoriatic Arthritis Drug Landscape Research Report 2024: Comprehensive Insights About 20+ Companies and 25+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Therapy, Acquisition, Arthritis, Psoriasis, Psoriatic arthritis, TEM, Inflammation, Malignancy, News, Atopic dermatitis, Route, Phase II, JAK1, KCNA3, JAK3, Discovery, Cell, Bristol Myers Squibb, Multiple sclerosis, Administration, Cytokine, Rheumatoid arthritis, TYK2, Clinical trial, NDA, Lluís Companys, Immune system, JAK2, Pharmaceutical industry

This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape.
  • A detailed picture of the Psoriatic Arthritis pipeline landscape is provided which includes the disease overview and Psoriatic Arthritis treatment guidelines.
  • The assessment part of the report embraces, in depth Psoriatic Arthritis commercial assessment and clinical assessment of the pipeline products under development.
  • Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Janus, Medical Subject Headings, Marketing, JAK2, INN, Immune system, Pigment, ATC, Woman, International, Disease, Language, Mouth, JAK, Acne, European Medicines Agency, Melanocyte, Face, Select, Depigmentation, Patient, JAK1, Diagnosis, Cell, Safety, Anatomy, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

NS-018, an Investigational Treatment for Myelofibrosis, Receives Orphan Drug Designation from the European Commission

Retrieved on: 
Tuesday, August 8, 2023
Ruxolitinib, Civil service commission, Fever, Survival, Bone marrow, Woman, MF, Abdominal pain, Bone pain, Spleen, Patient, Splenomegaly, European, JAK2, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, European Commission, Fatigue, Pharmaceutical industry

PARAMUS, N.J., Aug. 8, 2023 /PRNewswire/ -- NS Pharma, Inc. announced today that the European Commission (EC) has granted Orphan Drug Designation to NS-018 (ilginatinib) an oral, selective JAK2 inhibitor which is being investigated for the treatment of myelofibrosis (MF).

Key Points: 
  • NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai)
    PARAMUS, N.J., Aug. 8, 2023 /PRNewswire/ -- NS Pharma, Inc. announced today that the European Commission (EC) has granted Orphan Drug Designation to NS-018 (ilginatinib) an oral, selective JAK2 inhibitor which is being investigated for the treatment of myelofibrosis (MF).
  • The EC Orphan Drug Designation is issued to investigational treatments for diseases that affect fewer than 5 in 10,000 people in the European Union and are life-threatening or chronically debilitating.
  • The designation provides for a ten-year marketing exclusivity period.
  • In the US, NS-018 received Orphan Drug Designation by the U.S. Food and Drug Administration in December 2022.

Nitrase Therapeutics Announces Publication in the Journal of Biological Chemistry on the Role of Tyrosine Nitration in Cell Signaling and Cancer Biology

Retrieved on: 
Thursday, July 13, 2023
DAMP, Biochemistry, Database, Nitration, STAT1, Tyrosine, Phosphorylation, HER2, Hsps, CCL2, Bioorganic chemistry, Enzyme, Cancer, CXCL12, Sirtuin 2, LCK, Human, SHP2, DSM-IV codes, BCL2, Protein, Journal, B cell, HDAC2, Cell, Drug discovery, JAK2, Histone deacetylase 2, Sirtuin 6, Therapy, Janus kinase 2, SIRT6, SIRT2, Medical imaging

Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.

Key Points: 
  • Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.
  • The analysis revealed three major cellular networks that could be impacted by tyrosine nitration, resulting in altered protein function, localization, turnover, and protein-protein interactions.
  • Known sites of tyrosine nitration are also sites of phosphorylation, suggesting an extensive role for nitration in cell signaling, such that tyrosine nitration could profoundly interfere or alternatively complement tyrosine phosphorylation.
  • Tyrosine nitration is associated with different types of cancer by altering metabolic reprogramming and signaling.

Ajax Therapeutics Appoints Eric S. Fischer, PhD, to Scientific Advisory Board

Retrieved on: 
Wednesday, May 24, 2023
Biotechnology, Pharmaceutical, Health, Oncology, SAB, Biochemistry, Friedrich Miescher Institute for Biomedical Research, Dana–Farber Cancer Institute, JAK, University, Research, Biomedical Research, Computational chemistry, Doctor of Philosophy, Associate, Harvard Medical School, Pancreatic serous cystadenoma, Damon, Ajax, Translational research, Memorial Sloan Kettering Cancer Center, Proximity, JAK2, Pharmacology, Therapy, Chemical biology, MPN, Disease, Pharmaceutical industry, Leukemia, Thalidomide

Ajax Therapeutics, Inc. , a biopharmaceutical company applying computational chemistry and structure-based technologies to develop first-in-class and best-in-class JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Eric S. Fischer, PhD, to the Company’s Scientific Advisory Board (SAB).

Key Points: 
  • Ajax Therapeutics, Inc. , a biopharmaceutical company applying computational chemistry and structure-based technologies to develop first-in-class and best-in-class JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Eric S. Fischer, PhD, to the Company’s Scientific Advisory Board (SAB).
  • Dr. Fischer is a global leader in targeted protein degradation with appointments at Dana-Farber Cancer Institute (Dana-Farber) and Harvard Medical School.
  • He is a co-founder of Civetta Therapeutics, Neomorph, Inc. and Proximity Therapeutics.
  • Dr. Fischer completed his undergraduate training at the Universities of Hamburg and Basel and his doctoral training at the Friedrich Miescher Institute for Biomedical Research.

Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology

Retrieved on: 
Wednesday, May 10, 2023
Danske Bank, Bank of America, Ruxolitinib, NOT, FOR, Platelet, JAK1, Investor AB, BofA Securities, Latham & Watkins, BUY, USD, BVF, Acquisition, Patient, Blood, Vera, Hart–Scott–Rodino Antitrust Improvements Act, Cancer, CTI, ACRV1, JAK2, Rare, FDA, Bank, Thrombocytopenia, Pharmaceutical industry, Financial services, Security (finance), Swedish Orphan Biovitrum, Avatrombopag

STOCKHOLM, May 10, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) today announced that it has entered into an agreement and plan of merger with CTI BioPharma Corp. (CTI) under which Sobi has agreed to acquire CTI, a biopharmaceutical company focused on blood related cancers and rare diseases, by means of a tender offer.

Key Points: 
  • STOCKHOLM, May 10, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) today announced that it has entered into an agreement and plan of merger with CTI BioPharma Corp. (CTI) under which Sobi has agreed to acquire CTI, a biopharmaceutical company focused on blood related cancers and rare diseases, by means of a tender offer.
  • Highly complementary to Sobi's existing portfolio, specifically Doptelet®, expands Sobi's leading position in rare haematology and accelerates access for patients to both therapies globally.
  • The acquisition accelerates Sobi's strategy to build a leading franchise in rare haematology.
  • Mannheimer Swartling is acting as legal advisor to Sobi in relation to the debt financing and rights issue.

Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology

Retrieved on: 
Wednesday, May 10, 2023
Danske Bank, Bank of America, Ruxolitinib, NOT, FOR, Platelet, JAK1, Investor AB, BofA Securities, Latham & Watkins, BUY, USD, BVF, Acquisition, Patient, Blood, Vera, Hart–Scott–Rodino Antitrust Improvements Act, Cancer, CTI, ACRV1, JAK2, Rare, Bank, FDA, Thrombocytopenia, Pharmaceutical industry, Financial services, Dentistry, Security (finance), Swedish Orphan Biovitrum, Avatrombopag

STOCKHOLM, May 10, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) today announced that it has entered into an agreement and plan of merger with CTI BioPharma Corp. (CTI) under which Sobi has agreed to acquire CTI, a biopharmaceutical company focused on blood related cancers and rare diseases, by means of a tender offer.

Key Points: 
  • STOCKHOLM, May 10, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) today announced that it has entered into an agreement and plan of merger with CTI BioPharma Corp. (CTI) under which Sobi has agreed to acquire CTI, a biopharmaceutical company focused on blood related cancers and rare diseases, by means of a tender offer.
  • Highly complementary to Sobi's existing portfolio, specifically Doptelet®, expands Sobi's leading position in rare haematology and accelerates access for patients to both therapies globally.
  • The acquisition of CTI is the latest in a series of transformative transactions Sobi has conducted to build its leading rare haematology franchise."
  • Mannheimer Swartling is acting as legal advisor to Sobi in relation to the debt financing and rights issue.

NuProbe BDA Technology Enables Highly Sensitive Detection of Low-Level Variants for Oncology Research

Retrieved on: 
Wednesday, May 3, 2023
DNA, Cleveland Clinic, NGS, American Securities, Mutation, Research, Genomics, Biomarker, Doctor of Philosophy, Nanopore sequencing, MRD, BDA, Real-time, Laboratory, JAK2, DdPCR, PCR, Medical imaging

The research, done in collaboration with Cleveland Clinic, demonstrated concordance of the BDA technology to NGS and ddPCR and detection to 0.05% allele fraction.

Key Points: 
  • The research, done in collaboration with Cleveland Clinic, demonstrated concordance of the BDA technology to NGS and ddPCR and detection to 0.05% allele fraction.
  • BDA enables detection of low-frequency mutations such as those used for assessment of molecular residual disease (MRD).
  • In the study, 112 clinical samples were retrospectively tested using BDA technology in conjuction with qPCR, droplet digital PCR (ddPCR) without BDA, and NGS.
  • "BDA is a powerful technology that is broadly compatible with and improves the sensitivity of almost all DNA detection platforms."

Polycythemia Vera Epidemiology Forecast 2023-2032: Cases Expected to Increase Across Regions and Genders - ResearchAndMarkets.com

Retrieved on: 
Monday, March 20, 2023
Health, Biotechnology, Haematopoiesis, EU4, Ruxolitinib, Prevalence, Hydroxycarbamide, Epidemiology, PMF, Acute leukemia, Primary myelofibrosis, Risk, PV, Chlorambucil, Bone marrow failure, Polycythemia, Patient, Hematology, Blood, Splenomegaly, Busulfan, JAK2, United Kingdom, Diagnosis, HSC, Myeloproliferative neoplasm, FDA, Leukemia, Phenotype, MPN, Disease, Vaccine, Renewable energy

The "Polycythemia Vera - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Polycythemia Vera - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • The prevalence is projected to increase during the forecasted period
    In the United States, there were approximately 69,000 males and about 38,000 females affected with PV in 2022.
  • This 'Polycythemia Vera (PV)- Epidemiology Forecast-2032' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
  • Polycythemia Vera is a rare blood disease in which the body makes excessive red blood cells.